Proteins > Angiotensin-converting enzyme
Page last updated: 2024-08-07 15:56:58
Angiotensin-converting enzyme
An angiotensin-converting enzyme that is encoded in the genome of human. [PRO:WCB, UniProtKB:P12821]
Synonyms
ACE;
EC 3.2.1.-;
EC 3.4.15.1;
Dipeptidyl carboxypeptidase I;
Kininase II
Research
Bioassay Publications (53)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 12 (22.64) | 18.7374 |
| 1990's | 10 (18.87) | 18.2507 |
| 2000's | 13 (24.53) | 29.6817 |
| 2010's | 14 (26.42) | 24.3611 |
| 2020's | 4 (7.55) | 2.80 |
Compounds (97)
Drugs with Inhibition Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| gallic acid | Homo sapiens (human) | IC50 | 7,700.0000 | 1 | 1 |
| buspirone | Homo sapiens (human) | IC50 | 0.0240 | 1 | 1 |
| thiorphan | Homo sapiens (human) | IC50 | 0.2281 | 2 | 2 |
| losartan | Homo sapiens (human) | IC50 | 0.0190 | 1 | 1 |
| edetic acid | Homo sapiens (human) | IC50 | 14.0000 | 1 | 1 |
| glycylglycine | Homo sapiens (human) | IC50 | 7,244.3600 | 1 | 1 |
| captopril | Homo sapiens (human) | IC50 | 9.3070 | 23 | 26 |
| captopril | Homo sapiens (human) | Ki | 0.0020 | 1 | 1 |
| quinapril | Homo sapiens (human) | IC50 | 0.0083 | 4 | 6 |
| fosinoprilat | Homo sapiens (human) | Ki | 0.0015 | 1 | 1 |
| telmisartan | Homo sapiens (human) | Ki | 6.0000 | 1 | 1 |
| rentiapril | Homo sapiens (human) | IC50 | 0.0037 | 1 | 1 |
| libenzapril | Homo sapiens (human) | IC50 | 0.0070 | 1 | 1 |
| corilagin | Homo sapiens (human) | IC50 | 3,700.0000 | 1 | 1 |
| leucyl-alanine | Homo sapiens (human) | IC50 | 309.0300 | 1 | 1 |
| alanylproline | Homo sapiens (human) | IC50 | 127.0290 | 3 | 3 |
| moexipril | Homo sapiens (human) | IC50 | 0.0426 | 2 | 4 |
| glycyltryptophan | Homo sapiens (human) | IC50 | 30.1995 | 1 | 1 |
| zofenopril | Homo sapiens (human) | IC50 | 0.0004 | 1 | 1 |
| glycyltyrosine | Homo sapiens (human) | IC50 | 208.9300 | 1 | 1 |
| glycylleucine | Homo sapiens (human) | IC50 | 2,511.8900 | 1 | 1 |
| alanyltyrosine | Homo sapiens (human) | IC50 | 87.0964 | 1 | 1 |
| glycyl-l-phenylalanine | Homo sapiens (human) | IC50 | 616.7585 | 2 | 2 |
| alanylphenylalanine | Homo sapiens (human) | IC50 | 190.5460 | 1 | 1 |
| tryptophylglycine | Homo sapiens (human) | IC50 | 5,888.4400 | 1 | 1 |
| glycylaspartic acid | Homo sapiens (human) | IC50 | 9,120.1100 | 1 | 1 |
| n-glycylglutamic acid | Homo sapiens (human) | IC50 | 5,370.3200 | 1 | 1 |
| histidylglycine | Homo sapiens (human) | IC50 | 6,309.5700 | 1 | 1 |
| perindopril | Homo sapiens (human) | IC50 | 0.0015 | 1 | 1 |
| quinaprilat | Homo sapiens (human) | IC50 | 0.0583 | 3 | 5 |
| benzoylphenylalanyl-alanyl-proline | Homo sapiens (human) | IC50 | 1.3516 | 2 | 2 |
| way 100135 | Homo sapiens (human) | IC50 | 0.0339 | 1 | 1 |
| sq 28603 | Homo sapiens (human) | IC50 | 32.0000 | 1 | 1 |
| glycylglutamine | Homo sapiens (human) | IC50 | 7,079.4600 | 1 | 1 |
| 2-(4-morpholinyl)-4h-1-benzopyran-4-one | Homo sapiens (human) | IC50 | 13.4000 | 1 | 1 |
| 3-(mercaptomethyl)-2-oxo-1-piperidineacetic acid | Homo sapiens (human) | IC50 | 1.0000 | 1 | 1 |
| retrothiorphan | Homo sapiens (human) | IC50 | 1,000,000.0000 | 1 | 1 |
| a 58365a | Homo sapiens (human) | IC50 | 0.0316 | 1 | 1 |
| proline | Homo sapiens (human) | Ki | 86.0000 | 1 | 1 |
| phenylalanylarginine | Homo sapiens (human) | IC50 | 912.0110 | 1 | 1 |
| aspartylglycine | Homo sapiens (human) | IC50 | 14,125.4000 | 1 | 1 |
| compound 20 | Homo sapiens (human) | IC50 | 0.0061 | 5 | 6 |
| compound 20 | Homo sapiens (human) | Ki | 45.2000 | 1 | 1 |
| bb3497 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| n-valyltryptophan | Homo sapiens (human) | IC50 | 1.6283 | 3 | 3 |
| histidylleucine | Homo sapiens (human) | IC50 | 3,235.9400 | 1 | 1 |
| ceronapril | Homo sapiens (human) | IC50 | 0.0363 | 1 | 1 |
| succinylproline | Homo sapiens (human) | IC50 | 23.8066 | 2 | 2 |
| actinonin | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| phosphoramidon | Homo sapiens (human) | IC50 | 0.6150 | 2 | 2 |
| mln 4760 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| bucillamine | Homo sapiens (human) | IC50 | 7,244.3600 | 1 | 1 |
| omapatrilat | Homo sapiens (human) | IC50 | 0.0010 | 3 | 3 |
| omapatrilat | Homo sapiens (human) | Ki | 0.0038 | 4 | 4 |
| n-glycylalanine | Homo sapiens (human) | IC50 | 1,995.2600 | 1 | 1 |
| glycylvaline | Homo sapiens (human) | IC50 | 4,570.8800 | 1 | 1 |
| Geraniin | Homo sapiens (human) | IC50 | 400.0000 | 1 | 1 |
| glycylproline | Homo sapiens (human) | IC50 | 446.6840 | 2 | 2 |
| spiraprilat | Homo sapiens (human) | IC50 | 0.0008 | 1 | 1 |
| dasatinib | Homo sapiens (human) | Ki | 715.0000 | 1 | 1 |
| glycyllysine | Homo sapiens (human) | IC50 | 5,370.3200 | 1 | 1 |
| sitagliptin | Homo sapiens (human) | IC50 | 11.0000 | 1 | 1 |
| thiorphan | Homo sapiens (human) | IC50 | 3.7333 | 3 | 3 |
| norathyriol | Homo sapiens (human) | IC50 | 530.8000 | 1 | 1 |
| norathyriol | Homo sapiens (human) | Ki | 250.2000 | 1 | 1 |
| ellagic acid | Homo sapiens (human) | IC50 | 5,000.0000 | 1 | 1 |
| benzyloxycarbonyl-phe-ala-fluormethylketone | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| lisinopril | Homo sapiens (human) | IC50 | 0.0021 | 8 | 8 |
| lisinopril | Homo sapiens (human) | Ki | 0.0640 | 5 | 5 |
| benazepril | Homo sapiens (human) | IC50 | 0.0017 | 1 | 1 |
| ramipril | Homo sapiens (human) | IC50 | 0.0040 | 1 | 1 |
| enalapril | Homo sapiens (human) | IC50 | 0.3536 | 7 | 9 |
| enalaprilat anhydrous | Homo sapiens (human) | IC50 | 0.2405 | 11 | 13 |
| imidapril | Homo sapiens (human) | IC50 | 9.9000 | 1 | 1 |
| imidaprilat | Homo sapiens (human) | IC50 | 0.0017 | 1 | 1 |
| 1,3,5,6-tetrahydroxyxanthone | Homo sapiens (human) | IC50 | 69.2000 | 1 | 1 |
| 1,3,5,6-tetrahydroxyxanthone | Homo sapiens (human) | Ki | 34.2000 | 1 | 1 |
| alanylalanine | Homo sapiens (human) | IC50 | 616.5950 | 1 | 1 |
| trandolapril | Homo sapiens (human) | IC50 | 0.0009 | 1 | 1 |
| n(alpha)-phosphorylalanylproline | Homo sapiens (human) | IC50 | 0.7762 | 1 | 1 |
| n(alpha)-phosphorylalanylproline | Homo sapiens (human) | Ki | 0.0014 | 1 | 1 |
| alpha-aspartylalanine | Homo sapiens (human) | IC50 | 3,801.8900 | 1 | 1 |
| alanyltyrosine | Homo sapiens (human) | IC50 | 457.0880 | 1 | 1 |
| uk 81,252 | Homo sapiens (human) | Ki | 0.0929 | 2 | 2 |
| prolylglycine | Homo sapiens (human) | IC50 | 16,982.4000 | 1 | 1 |
| glutamylalanine | Homo sapiens (human) | IC50 | 10,000.0000 | 1 | 1 |
| glutaminyl-glycine | Homo sapiens (human) | IC50 | 7,413.1000 | 1 | 1 |
| methionylglycine | Homo sapiens (human) | IC50 | 4,786.3000 | 1 | 1 |
| phenylalanyl-valine | Homo sapiens (human) | IC50 | 52.4808 | 1 | 1 |
| alanylglycine | Homo sapiens (human) | IC50 | 2,511.8900 | 1 | 1 |
| valyltyrosine | Homo sapiens (human) | IC50 | 21.8776 | 1 | 1 |
| lysylglycine | Homo sapiens (human) | IC50 | 3,235.9400 | 1 | 1 |
| glycylhistidine | Homo sapiens (human) | IC50 | 3,090.3000 | 1 | 1 |
| isoleucyl-tyrosine | Homo sapiens (human) | IC50 | 3.7077 | 2 | 2 |
| fosinopril | Homo sapiens (human) | IC50 | 0.0010 | 1 | 1 |
| rxp 407 | Homo sapiens (human) | Ki | 3.7535 | 2 | 2 |
| prolylvaline | Homo sapiens (human) | IC50 | 416.8690 | 2 | 2 |
| cgs 35066 | Homo sapiens (human) | IC50 | 1.1610 | 2 | 2 |
| nicotianamine | Homo sapiens (human) | IC50 | 18.7000 | 1 | 1 |
| 3,4,5,6-tetrahydroxyxanthone | Homo sapiens (human) | IC50 | 238.5000 | 1 | 1 |
| 3,4,5,6-tetrahydroxyxanthone | Homo sapiens (human) | Ki | 126.0000 | 1 | 1 |
| s 3304 | Homo sapiens (human) | IC50 | 1.0000 | 1 | 1 |
| grassystatin a | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| novobiocin | Homo sapiens (human) | Ki | 167.0000 | 1 | 1 |
Drugs with Activation Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| captopril | Homo sapiens (human) | EC50 | 487.4692 | 3 | 3 |
Drugs with Other Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| bradykinin | Homo sapiens (human) | Km | 0.1800 | 1 | 1 |
Validation of EGSITE2, a mixed integer program for deducing objective site models for experimental binding data.Journal of medicinal chemistry, , Sep-26, Volume: 40, Issue:20, 1997
Exploration of neutral endopeptidase active site by a series of new thiol-containing inhibitors.Journal of medicinal chemistry, , Jan-08, Volume: 36, Issue:1, 1993
Zinc enzymes in medicinal chemistry.European journal of medicinal chemistry, , Dec-15, Volume: 226, 2021
Metabolomics-Guided Discovery of Microginin Peptides from Cultures of the Cyanobacterium Microcystis aeruginosa.Journal of natural products, , 02-23, Volume: 81, Issue:2, 2018
Quest for Novel Chemical Entities through Incorporation of Silicon in Drug Scaffolds.Journal of medicinal chemistry, , 05-10, Volume: 61, Issue:9, 2018
Top-down Targeted Metabolomics Reveals a Sulfur-Containing Metabolite with Inhibitory Activity against Angiotensin-Converting Enzyme in Asparagus officinalis.Journal of natural products, , May-22, Volume: 78, Issue:5, 2015
Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-β hydrolysis.European journal of medicinal chemistry, , May-22, Volume: 79, 2014
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.Journal of medicinal chemistry, , Nov-14, Volume: 56, Issue:21, 2013
Investigating the selectivity of metalloenzyme inhibitors.Journal of medicinal chemistry, , Oct-24, Volume: 56, Issue:20, 2013
Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors.Bioorganic & medicinal chemistry letters, , Aug-15, Volume: 19, Issue:16, 2009
Synthesis and biological evaluation of N-mercaptoacylproline and N-mercaptoacylthiazolidine-4-carboxylic acid derivatives as leukotriene A4 hydrolase inhibitors.Bioorganic & medicinal chemistry letters, , Aug-15, Volume: 18, Issue:16, 2008
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.Journal of medicinal chemistry, , Jul-24, Volume: 51, Issue:14, 2008
The molecular basis for the selection of captopril cis and trans conformations by angiotensin I converting enzyme.Bioorganic & medicinal chemistry letters, , Oct-01, Volume: 16, Issue:19, 2006
Designed multiple ligands. An emerging drug discovery paradigm.Journal of medicinal chemistry, , Oct-20, Volume: 48, Issue:21, 2005
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
Validation of EGSITE2, a mixed integer program for deducing objective site models for experimental binding data.Journal of medicinal chemistry, , Sep-26, Volume: 40, Issue:20, 1997
Three-dimensional quantitative structure-activity relationship of angiotesin-converting enzyme and thermolysin inhibitors. II. A comparison of CoMFA models incorporating molecular orbital fields and desolvation free energies based on active-analog and comJournal of medicinal chemistry, , Aug-06, Volume: 36, Issue:16, 1993
Angiotensin converting enzyme inhibitors: spirapril and related compounds.Journal of medicinal chemistry, , Volume: 32, Issue:7, 1989
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.Journal of medicinal chemistry, , Volume: 29, Issue:10, 1986
Synthesis and biological activity of modified peptide inhibitors of angiotensin-converting enzyme.Journal of medicinal chemistry, , Volume: 28, Issue:9, 1985
Angiotensin converting enzyme inhibitors: structure-activity profile of 1-benzazepin-2-one derivatives.Journal of medicinal chemistry, , Volume: 28, Issue:11, 1985
Conformational analysis and active site modelling of angiotensin-converting enzyme inhibitors.Journal of medicinal chemistry, , Volume: 28, Issue:3, 1985
Angiotensin-converting enzyme inhibitors: synthesis and biological activity of acyl tripeptide analogues of enalapril.Journal of medicinal chemistry, , Volume: 28, Issue:4, 1985
Derivatives of the potent angiotensin converting enzyme inhibitor 5(S)-benzamido-4-oxo-6-phenylhexanoyl-L-proline: effect of changes at positions 2 and 5 of the hexanoic acid portion.Journal of medicinal chemistry, , Volume: 25, Issue:11, 1982
Novel synthesis of (S)-1-[5-(benzoylamino)-1,4-dioxo-6-phenylhexyl]-L-proline and analogues: potent angiotensin converting enzyme inhibitors.Journal of medicinal chemistry, , Volume: 24, Issue:8, 1981
Synthesis and angiotensin-converting enzyme inhibitory activity of 3-(Mercaptomethyl)-2-oxo-1-pyrrolidineacetic acids and 3-(Mercaptomethyl)-2-oxo-1-piperidineacetic acids.Journal of medicinal chemistry, , Volume: 24, Issue:1, 1981
Chemical and pharmaceutical studies on medicinal plants in Paraguay. Geraniin, an angiotensin-converting enzyme inhibitor from "paraparai mi," Phyllanthus niruri.Journal of natural products, , Volume: 51, Issue:2
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
Molecular and crystal structures of MDL27,467A hydrochloride and quinapril hydrochloride, two ester derivatives of potent angiotensin converting enzyme inhibitors.Journal of medicinal chemistry, , Volume: 34, Issue:2, 1991
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.Journal of medicinal chemistry, , Volume: 29, Issue:10, 1986
Synthesis and biological activity of modified peptide inhibitors of angiotensin-converting enzyme.Journal of medicinal chemistry, , Volume: 28, Issue:9, 1985
Three-dimensional quantitative structure-activity relationship of angiotesin-converting enzyme and thermolysin inhibitors. II. A comparison of CoMFA models incorporating molecular orbital fields and desolvation free energies based on active-analog and comJournal of medicinal chemistry, , Aug-06, Volume: 36, Issue:16, 1993
Studies on angiotensin converting enzyme inhibitors. 4. Synthesis and angiotensin converting enzyme inhibitory activities of 3-acyl-1-alkyl-2-oxoimidazolidine-4-carboxylic acid derivatives.Journal of medicinal chemistry, , Volume: 32, Issue:2, 1989
Conformationally restricted inhibitors of angiotensin converting enzyme: synthesis and computations.Journal of medicinal chemistry, , Volume: 29, Issue:2, 1986
Amino acid side chain descriptors for quantitative structure-activity relationship studies of peptide analogues.Journal of medicinal chemistry, , Jul-07, Volume: 38, Issue:14, 1995
Three-dimensional quantitative structure-activity relationship of angiotesin-converting enzyme and thermolysin inhibitors. II. A comparison of CoMFA models incorporating molecular orbital fields and desolvation free energies based on active-analog and comJournal of medicinal chemistry, , Aug-06, Volume: 36, Issue:16, 1993
Molecular and crystal structures of MDL27,467A hydrochloride and quinapril hydrochloride, two ester derivatives of potent angiotensin converting enzyme inhibitors.Journal of medicinal chemistry, , Volume: 34, Issue:2, 1991
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.Journal of medicinal chemistry, , Volume: 29, Issue:10, 1986
Synthesis and biological activity of modified peptide inhibitors of angiotensin-converting enzyme.Journal of medicinal chemistry, , Volume: 28, Issue:9, 1985
Synthesis of novel keto-ACE analogues as domain-selective angiotensin I-converting enzyme inhibitors.Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 16, Issue:17, 2006
Three-dimensional quantitative structure-activity relationship of angiotesin-converting enzyme and thermolysin inhibitors. II. A comparison of CoMFA models incorporating molecular orbital fields and desolvation free energies based on active-analog and comJournal of medicinal chemistry, , Aug-06, Volume: 36, Issue:16, 1993
Angiotensin-converting enzyme inhibitors: synthesis and biological activity of acyl tripeptide analogues of enalapril.Journal of medicinal chemistry, , Volume: 28, Issue:4, 1985
Derivatives of the potent angiotensin converting enzyme inhibitor 5(S)-benzamido-4-oxo-6-phenylhexanoyl-L-proline: effect of changes at positions 2 and 5 of the hexanoic acid portion.Journal of medicinal chemistry, , Volume: 25, Issue:11, 1982
Angiotensin converting enzyme inhibitors: modifications of a tripeptide analogue.Journal of medicinal chemistry, , Volume: 25, Issue:8, 1982
Novel synthesis of (S)-1-[5-(benzoylamino)-1,4-dioxo-6-phenylhexyl]-L-proline and analogues: potent angiotensin converting enzyme inhibitors.Journal of medicinal chemistry, , Volume: 24, Issue:8, 1981
Amino acid side chain descriptors for quantitative structure-activity relationship studies of peptide analogues.Journal of medicinal chemistry, , Jul-07, Volume: 38, Issue:14, 1995
PRO_LIGAND: an approach to de novo molecular design. 2. Design of novel molecules from molecular field analysis (MFA) models and pharmacophores.Journal of medicinal chemistry, , Nov-11, Volume: 37, Issue:23, 1994
Studies on angiotensin converting enzyme inhibitors. 4. Synthesis and angiotensin converting enzyme inhibitory activities of 3-acyl-1-alkyl-2-oxoimidazolidine-4-carboxylic acid derivatives.Journal of medicinal chemistry, , Volume: 32, Issue:2, 1989
Top-down Targeted Metabolomics Reveals a Sulfur-Containing Metabolite with Inhibitory Activity against Angiotensin-Converting Enzyme in Asparagus officinalis.Journal of natural products, , May-22, Volume: 78, Issue:5, 2015
Three-dimensional quantitative structure-activity relationship of angiotesin-converting enzyme and thermolysin inhibitors. II. A comparison of CoMFA models incorporating molecular orbital fields and desolvation free energies based on active-analog and comJournal of medicinal chemistry, , Aug-06, Volume: 36, Issue:16, 1993
[no title available]ACS medicinal chemistry letters, , Jan-10, Volume: 10, Issue:1, 2019
Molecular Basis for Multiple Omapatrilat Binding Sites within the ACE C-Domain: Implications for Drug Design.Journal of medicinal chemistry, , 11-21, Volume: 61, Issue:22, 2018
Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors.Journal of medicinal chemistry, , Jan-14, Volume: 53, Issue:1, 2010
Amino acid side chain descriptors for quantitative structure-activity relationship studies of peptide analogues.Journal of medicinal chemistry, , Jul-07, Volume: 38, Issue:14, 1995
Three-dimensional quantitative structure-activity relationship of angiotesin-converting enzyme and thermolysin inhibitors. II. A comparison of CoMFA models incorporating molecular orbital fields and desolvation free energies based on active-analog and comJournal of medicinal chemistry, , Aug-06, Volume: 36, Issue:16, 1993
Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin-Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme.Journal of medicinal chemistry, , 05-28, Volume: 63, Issue:10, 2020
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
Probing the Requirements for Dual Angiotensin-Converting Enzyme C-Domain Selective/Neprilysin Inhibition.Journal of medicinal chemistry, , 02-24, Volume: 65, Issue:4, 2022
Zinc enzymes in medicinal chemistry.European journal of medicinal chemistry, , Dec-15, Volume: 226, 2021
Therapeutic investigations of novel indoxyl-based indolines: A drug target validation and Structure-Activity Relationship of angiotensin-converting enzyme inhibitors with cardiovascular regulation and thrombolytic potential.European journal of medicinal chemistry, , Dec-01, Volume: 141, 2017
Perindopril and ramipril phosphonate analogues as a new class of angiotensin converting enzyme inhibitors.Bioorganic & medicinal chemistry, , Nov-15, Volume: 21, Issue:22, 2013
Synthesis of novel keto-ACE analogues as domain-selective angiotensin I-converting enzyme inhibitors.Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 16, Issue:17, 2006
Synthesis and molecular modeling of a lisinopril-tryptophan analogue inhibitor of angiotensin I-converting enzyme.Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 16, Issue:17, 2006
Computer-aided selection of potential antihypertensive compounds with dual mechanism of action.Journal of medicinal chemistry, , Jul-17, Volume: 46, Issue:15, 2003
2002 Alfred Burger Award Address in Medicinal Chemistry. Natural products and design: interrelated approaches in drug discovery.Journal of medicinal chemistry, , Dec-19, Volume: 45, Issue:26, 2002
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
Excursions in drug discovery.Journal of medicinal chemistry, , Jul-23, Volume: 36, Issue:15, 1993
Three-dimensional quantitative structure-activity relationship of angiotesin-converting enzyme and thermolysin inhibitors. II. A comparison of CoMFA models incorporating molecular orbital fields and desolvation free energies based on active-analog and comJournal of medicinal chemistry, , Aug-06, Volume: 36, Issue:16, 1993
2002 Alfred Burger Award Address in Medicinal Chemistry. Natural products and design: interrelated approaches in drug discovery.Journal of medicinal chemistry, , Dec-19, Volume: 45, Issue:26, 2002
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
Molecular and crystal structures of MDL27,467A hydrochloride and quinapril hydrochloride, two ester derivatives of potent angiotensin converting enzyme inhibitors.Journal of medicinal chemistry, , Volume: 34, Issue:2, 1991
Angiotensin converting enzyme inhibitors: spirapril and related compounds.Journal of medicinal chemistry, , Volume: 32, Issue:7, 1989
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.Journal of medicinal chemistry, , Volume: 29, Issue:10, 1986
Synthesis and biological activity of modified peptide inhibitors of angiotensin-converting enzyme.Journal of medicinal chemistry, , Volume: 28, Issue:9, 1985
Angiotensin converting enzyme inhibitors: structure-activity profile of 1-benzazepin-2-one derivatives.Journal of medicinal chemistry, , Volume: 28, Issue:11, 1985
Approaches towards the development of chimeric DPP4/ACE inhibitors for treating metabolic syndrome.Bioorganic & medicinal chemistry letters, , 06-01, Volume: 27, Issue:11, 2017
2002 Alfred Burger Award Address in Medicinal Chemistry. Natural products and design: interrelated approaches in drug discovery.Journal of medicinal chemistry, , Dec-19, Volume: 45, Issue:26, 2002
Validation of EGSITE2, a mixed integer program for deducing objective site models for experimental binding data.Journal of medicinal chemistry, , Sep-26, Volume: 40, Issue:20, 1997
Excursions in drug discovery.Journal of medicinal chemistry, , Jul-23, Volume: 36, Issue:15, 1993
Molecular and crystal structures of MDL27,467A hydrochloride and quinapril hydrochloride, two ester derivatives of potent angiotensin converting enzyme inhibitors.Journal of medicinal chemistry, , Volume: 34, Issue:2, 1991
Angiotensin converting enzyme inhibitors: spirapril and related compounds.Journal of medicinal chemistry, , Volume: 32, Issue:7, 1989
Studies on angiotensin converting enzyme inhibitors. 4. Synthesis and angiotensin converting enzyme inhibitory activities of 3-acyl-1-alkyl-2-oxoimidazolidine-4-carboxylic acid derivatives.Journal of medicinal chemistry, , Volume: 32, Issue:2, 1989
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.Journal of medicinal chemistry, , Volume: 29, Issue:10, 1986
Conformationally restricted inhibitors of angiotensin converting enzyme: synthesis and computations.Journal of medicinal chemistry, , Volume: 29, Issue:2, 1986
Synthesis and biological activity of modified peptide inhibitors of angiotensin-converting enzyme.Journal of medicinal chemistry, , Volume: 28, Issue:9, 1985
Angiotensin-converting enzyme inhibitors: synthesis and biological activity of acyl tripeptide analogues of enalapril.Journal of medicinal chemistry, , Volume: 28, Issue:4, 1985
Amino acid side chain descriptors for quantitative structure-activity relationship studies of peptide analogues.Journal of medicinal chemistry, , Jul-07, Volume: 38, Issue:14, 1995
PRO_LIGAND: an approach to de novo molecular design. 2. Design of novel molecules from molecular field analysis (MFA) models and pharmacophores.Journal of medicinal chemistry, , Nov-11, Volume: 37, Issue:23, 1994
Amino acid side chain descriptors for quantitative structure-activity relationship studies of peptide analogues.Journal of medicinal chemistry, , Jul-07, Volume: 38, Issue:14, 1995
Three-dimensional quantitative structure-activity relationship of angiotesin-converting enzyme and thermolysin inhibitors. II. A comparison of CoMFA models incorporating molecular orbital fields and desolvation free energies based on active-analog and comJournal of medicinal chemistry, , Aug-06, Volume: 36, Issue:16, 1993
Enables
This protein enables 16 target(s):
| Target | Category | Definition |
|---|
| endopeptidase activity | molecular function | Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain. [http://merops.sanger.ac.uk/about/glossary.htm#ENDOPEPTIDASE] |
| carboxypeptidase activity | molecular function | Catalysis of the hydrolysis of a single C-terminal amino acid residue from a polypeptide chain. [https://www.ebi.ac.uk/merops/about/glossary.shtml#CARBOXYPEPTIDASE] |
| metalloendopeptidase activity | molecular function | Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain by a mechanism in which water acts as a nucleophile, one or two metal ions hold the water molecule in place, and charged amino acid side chains are ligands for the metal ions. [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE, https://www.ebi.ac.uk/merops/about/glossary.shtml#ENDOPEPTIDASE] |
| calmodulin binding | molecular function | Binding to calmodulin, a calcium-binding protein with many roles, both in the calcium-bound and calcium-free states. [GOC:krc] |
| peptidase activity | molecular function | Catalysis of the hydrolysis of a peptide bond. A peptide bond is a covalent bond formed when the carbon atom from the carboxyl group of one amino acid shares electrons with the nitrogen atom from the amino group of a second amino acid. [GOC:jl, ISBN:0815332181] |
| metallopeptidase activity | molecular function | Catalysis of the hydrolysis of peptide bonds by a mechanism in which water acts as a nucleophile, one or two metal ions hold the water molecule in place, and charged amino acid side chains are ligands for the metal ions. [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE] |
| exopeptidase activity | molecular function | Catalysis of the hydrolysis of a peptide bond not more than three residues from the N- or C-terminus of a polypeptide chain, in a reaction that requires a free N-terminal amino group, C-terminal carboxyl group or both. [https://www.ebi.ac.uk/merops/about/glossary.shtml#EXOPEPTIDASE] |
| tripeptidyl-peptidase activity | molecular function | Catalysis of the release of an N-terminal tripeptide from a polypeptide. [GOC:mah] |
| peptidyl-dipeptidase activity | molecular function | Catalysis of the release of C-terminal dipeptides from a polypeptide chain. [GOC:mb] |
| zinc ion binding | molecular function | Binding to a zinc ion (Zn). [GOC:ai] |
| chloride ion binding | molecular function | Binding to a chloride ion (Cl-). [GOC:mah] |
| mitogen-activated protein kinase kinase binding | molecular function | Binding to a mitogen-activated protein kinase kinase, a protein that can phosphorylate a MAP kinase. [GOC:mah] |
| bradykinin receptor binding | molecular function | Binding to a bradykinin receptor. [GOC:mah, GOC:nln] |
| mitogen-activated protein kinase binding | molecular function | Binding to a mitogen-activated protein kinase. [GOC:ai] |
| metallodipeptidase activity | molecular function | Catalysis of the hydrolysis of a dipeptide by a mechanism in which water acts as a nucleophile, one or two metal ions hold the water molecule in place, and charged amino acid side chains are ligands for the metal ions. [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE] |
| heterocyclic compound binding | molecular function | Binding to heterocyclic compound. [GOC:TermGenie] |
Located In
This protein is located in 10 target(s):
| Target | Category | Definition |
|---|
| extracellular region | cellular component | The space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane. This term covers the host cell environment outside an intracellular parasite. [GOC:go_curators] |
| extracellular space | cellular component | That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid. [ISBN:0198547684] |
| lysosome | cellular component | A small lytic vacuole that has cell cycle-independent morphology found in most animal cells and that contains a variety of hydrolases, most of which have their maximal activities in the pH range 5-6. The contained enzymes display latency if properly isolated. About 40 different lysosomal hydrolases are known and lysosomes have a great variety of morphologies and functions. [GOC:mah, ISBN:0198506732] |
| endosome | cellular component | A vacuole to which materials ingested by endocytosis are delivered. [ISBN:0198506732, PMID:19696797] |
| plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
| external side of plasma membrane | cellular component | The leaflet of the plasma membrane that faces away from the cytoplasm and any proteins embedded or anchored in it or attached to its surface. [GOC:dos, GOC:tb] |
| basal plasma membrane | cellular component | The region of the plasma membrane located at the basal end of the cell. Often used in reference to animal polarized epithelial membranes, where the basal membrane is the part attached to the extracellular matrix, or in plant cells, where the basal membrane is defined with respect to the zygotic axis. [GOC:go_curators] |
| brush border membrane | cellular component | The portion of the plasma membrane surrounding the brush border. [GOC:mah] |
| extracellular exosome | cellular component | A vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane. Extracellular exosomes, also simply called exosomes, have a diameter of about 40-100 nm. [GOC:BHF, GOC:mah, GOC:vesicles, PMID:15908444, PMID:17641064, PMID:19442504, PMID:19498381, PMID:22418571, PMID:24009894] |
| sperm midpiece | cellular component | The highly organized segment of the sperm flagellum which begins at the connecting piece and is characterized by the presence of 9 outer dense fibers (ODFs) that lie outside each of the 9 outer axonemal microtubule doublets and by a sheath of mitochondria that encloses the ODFs and the axoneme; the midpiece terminates about one-fourth of the way down the sperm flagellum at the annulus, which marks the beginning of the principal piece. [GOC:cjm, MP:0009831] |
Active In
This protein is active in 2 target(s):
| Target | Category | Definition |
|---|
| extracellular space | cellular component | That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid. [ISBN:0198547684] |
| plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
Involved In
This protein is involved in 56 target(s):
| Target | Category | Definition |
|---|
| response to hypoxia | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level. [GOC:hjd] |
| kidney development | biological process | The process whose specific outcome is the progression of the kidney over time, from its formation to the mature structure. The kidney is an organ that filters the blood and/or excretes the end products of body metabolism in the form of urine. [GOC:dph, GOC:mtg_kidney_jan10, ISBN:0124020607, ISBN:0721662544] |
| blood vessel remodeling | biological process | The reorganization or renovation of existing blood vessels. [GOC:hjd] |
| angiotensin maturation | biological process | The process leading to the attainment of the full functional capacity of angiotensin by conversion of angiotensinogen into mature angiotensin in the blood. [ISBN:0721643949] |
| regulation of renal output by angiotensin | biological process | The process in which angiotensin directly modulates the rate of urine output by the kidney. [GOC:dph, GOC:mtg_cardio, GOC:tb, ISBN:0721643949] |
| neutrophil mediated immunity | biological process | Any process involved in the carrying out of an immune response by a neutrophil. [GO_REF:0000022, GOC:add, ISBN:0781735149] |
| antigen processing and presentation of peptide antigen via MHC class I | biological process | The process in which an antigen-presenting cell expresses a peptide antigen on its cell surface in association with an MHC class I protein complex. Class I here refers to classical class I molecules. [GOC:add, ISBN:0781735149, PMID:15224092, PMID:15771591] |
| regulation of systemic arterial blood pressure by renin-angiotensin | biological process | The process in which renin-angiotensin modulates the force with which blood passes through the circulatory system. [GOC:mtg_cardio] |
| proteolysis | biological process | The hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their peptide bonds. [GOC:bf, GOC:mah] |
| spermatogenesis | biological process | The developmental process by which male germ line stem cells self renew or give rise to successive cell types resulting in the development of a spermatozoa. [GOC:jid, ISBN:9780878933846, PMID:28073824, PMID:30990821] |
| female pregnancy | biological process | The set of physiological processes that allow an embryo or foetus to develop within the body of a female animal. It covers the time from fertilization of a female ovum by a male spermatozoon until birth. [ISBN:0192800825] |
| regulation of blood pressure | biological process | Any process that modulates the force with which blood travels through the circulatory system. The process is controlled by a balance of processes that increase pressure and decrease pressure. [GOC:dph, GOC:mtg_cardio, ISBN:0721643949] |
| male gonad development | biological process | The process whose specific outcome is the progression of the male gonad over time, from its formation to the mature structure. [GOC:jid] |
| response to xenobiotic stimulus | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a xenobiotic, a compound foreign to the organim exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical. [GOC:jl, GOC:krc] |
| embryo development ending in birth or egg hatching | biological process | The process whose specific outcome is the progression of an embryo over time, from zygote formation until the end of the embryonic life stage. The end of the embryonic life stage is organism-specific and may be somewhat arbitrary; for mammals it is usually considered to be birth, for insects the hatching of the first instar larva from the eggshell. [GOC:go_curators, GOC:isa_complete, GOC:mtg_sensu] |
| post-transcriptional regulation of gene expression | biological process | Any process that modulates the frequency, rate or extent of gene expression after the production of an RNA transcript. [GOC:dph, GOC:tb] |
| negative regulation of gene expression | biological process | Any process that decreases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product (protein or RNA). [GOC:txnOH-2018] |
| substance P catabolic process | biological process | The chemical reactions and pathways resulting in the breakdown of the neuropeptide substance P. [GOC:BHF, GOC:rl] |
| bradykinin catabolic process | biological process | The chemical reactions and pathways resulting in the breakdown of the peptide bradykinin. [GOC:BHF, GOC:rl] |
| regulation of smooth muscle cell migration | biological process | Any process that modulates the frequency, rate or extent of smooth muscle cell migration. [CL:0000192, GOC:mtg_muscle] |
| regulation of vasoconstriction | biological process | Any process that modulates the frequency, rate or extent of reductions in the diameter of blood vessels. [GOC:jl] |
| animal organ regeneration | biological process | The regrowth of a lost or destroyed animal organ. [GOC:mah] |
| response to nutrient levels | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus reflecting the presence, absence, or concentration of nutrients. [GOC:mah] |
| response to lipopolysaccharide | biological process | Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipopolysaccharide stimulus; lipopolysaccharide is a major component of the cell wall of gram-negative bacteria. [GOC:add, ISBN:0721601464] |
| mononuclear cell proliferation | biological process | The expansion of a mononuclear cell population by cell division. A mononuclear cell is a leukocyte with a single non-segmented nucleus in the mature form. [GOC:add] |
| response to laminar fluid shear stress | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a laminar fluid shear stress stimulus. Laminar fluid flow is the force acting on an object in a system where the fluid is moving across a solid surface in parallel layers. As an example, laminar shear stress can be seen where blood flows against the luminal side of blood vessel walls. [GOC:ecd] |
| angiotensin-activated signaling pathway | biological process | A G protein-coupled receptor signaling pathway initiated by angiotensin II binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. [GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:nhn, GOC:signaling, PMID:10977869] |
| vasoconstriction | biological process | A decrease in the diameter of blood vessels, especially arteries, due to constriction of smooth muscle cells that line the vessels, and usually causing an increase in blood pressure. [GOC:pr, ISBN:0192800752] |
| hormone metabolic process | biological process | The chemical reactions and pathways involving any hormone, naturally occurring substances secreted by specialized cells that affects the metabolism or behavior of other cells possessing functional receptors for the hormone. [GOC:jl] |
| hormone catabolic process | biological process | The chemical reactions and pathways resulting in the breakdown of any hormone, naturally occurring substances secreted by specialized cells that affects the metabolism or behavior of other cells possessing functional receptors for the hormone. [GOC:jl] |
| eating behavior | biological process | The specific behavior of an organism relating to the intake of food, any substance (usually solid) that can be metabolized by an organism to give energy and build tissue. [GOC:jl, GOC:pr, PMID:19361967] |
| positive regulation of apoptotic process | biological process | Any process that activates or increases the frequency, rate or extent of cell death by apoptotic process. [GOC:jl, GOC:mtg_apoptosis] |
| peptide catabolic process | biological process | The chemical reactions and pathways resulting in the breakdown of peptides, compounds of 2 or more (but usually less than 100) amino acids where the alpha carboxyl group of one is bound to the alpha amino group of another. [GOC:jl] |
| positive regulation of vasoconstriction | biological process | Any process that activates or increases the frequency, rate or extent of vasoconstriction. [GOC:go_curators] |
| negative regulation of glucose import | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of the import of the hexose monosaccharide glucose into a cell or organelle. [GOC:ai] |
| regulation of synaptic plasticity | biological process | A process that modulates synaptic plasticity, the ability of synapses to change as circumstances require. They may alter function, such as increasing or decreasing their sensitivity, or they may increase or decrease in actual numbers. [GOC:dph, GOC:jid, GOC:tb, PMID:11891290] |
| lung alveolus development | biological process | The process whose specific outcome is the progression of the alveolus over time, from its formation to the mature structure. The alveolus is a sac for holding air in the lungs; formed by the terminal dilation of air passageways. [GOC:mtg_lung, PMID:9751757] |
| amyloid-beta metabolic process | biological process | The chemical reactions and pathways involving amyloid-beta, a glycoprotein associated with Alzheimer's disease, and its precursor, amyloid precursor protein (APP). [GOC:ai] |
| arachidonic acid secretion | biological process | The controlled release of arachidonic acid from a cell or a tissue. [GOC:ai] |
| positive regulation of neurogenesis | biological process | Any process that activates or increases the frequency, rate or extent of neurogenesis, the generation of cells within the nervous system. [GOC:ai] |
| heart contraction | biological process | The multicellular organismal process in which the heart decreases in volume in a characteristic way to propel blood through the body. [GOC:dph] |
| regulation of angiotensin metabolic process | biological process | Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving angiotensin. [GOC:dph, GOC:tb] |
| hematopoietic stem cell differentiation | biological process | The process in which a relatively unspecialized cell acquires specialized features of a hematopoietic stem cell. A stem cell is a cell that retains the ability to divide and proliferate throughout life to provide progenitor cells that can differentiate into specialized cells. [GOC:bf, GOC:BHF, GOC:dph, GOC:rl, PMID:15378083] |
| angiogenesis involved in coronary vascular morphogenesis | biological process | Blood vessel formation in the heart when new vessels emerge from the proliferation of pre-existing blood vessels. [GOC:mtg_heart] |
| cellular response to glucose stimulus | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glucose stimulus. [GOC:mah] |
| response to dexamethasone | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a dexamethasone stimulus. [GOC:mah, GOC:yaf] |
| cell proliferation in bone marrow | biological process | The multiplication or reproduction of cells, resulting in the expansion of a cell population in the bone marrow. [GOC:mah, GOC:yaf, PMID:17063141] |
| regulation of heart rate by cardiac conduction | biological process | A cardiac conduction process that modulates the frequency or rate of heart contraction. [GOC:BHF, GOC:mtg_cardiac_conduct_nov11] |
| negative regulation of calcium ion import | biological process | Any process that decreases the rate, frequency, or extent of the directed movement of calcium ions into a cell or organelle. [GOC:BHF] |
| response to thyroid hormone | biological process | A change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a thyroid hormone stimulus. [GOC:sjw, PMID:9916872] |
| blood vessel diameter maintenance | biological process | Any process that modulates the diameter of blood vessels. [GOC:pr] |
| regulation of hematopoietic stem cell proliferation | biological process | Any process that modulates the frequency, rate or extent of hematopoietic stem cell proliferation. [GOC:TermGenie, PMID:23403623] |
| negative regulation of gap junction assembly | biological process | Any process that stops, prevents or reduces the frequency, rate or extent of gap junction assembly. [GO_REF:0000058, GOC:BHF, GOC:mtg_cardiac_conduct_nov11, GOC:rl, GOC:TermGenie, PMID:25017399] |
| cellular response to aldosterone | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an aldosterone stimulus. [GO_REF:0000071, GOC:TermGenie, PMID:17644563] |
| positive regulation of peptidyl-cysteine S-nitrosylation | biological process | Any process that activates or increases the frequency, rate or extent of peptidyl-cysteine S-nitrosylation. [GOC:obol] |
| positive regulation of systemic arterial blood pressure | biological process | The process that increases the force with which blood travels through the systemic arterial circulatory system. [GOC:mtg_cardio] |